BioXcel Therapeutics – Consensus Indicates Potential 129.0% Upside

Broker Ratings

BioXcel Therapeutics found using ticker (BTAI) now have 10 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The range between the high target price and low target price is between 175 and 60 with a mean TP of 105.8. With the stocks previous close at 46.2 this is indicating there is a potential upside of 129.0%. The day 50 moving average is 47.81 and the 200 moving average now moves to 48.28. The market capitalisation for the company is $1,273m. Company Website:

BioXcel Therapeutics, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics has a collaboration with Merck KGaA; Nektar Therapeutics; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics is a subsidiary of BioXcel Corporation.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index